RB regulates the stability and the apoptotic function of p53 via MDM2

Molecular Cell

Volumn 3, Issue 2, 1999, Pages 181-193

  Hsieh, Jung Kuang ^a   Chan, Florence S G ^a   O'Connor, Daniel J ^a   Mittnacht, Sibylle ^b   Zhong, Shan ^a   Xin, Lu ^c  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA PROTEIN;

APOPTOSIS; ARTICLE; BINDING SITE; CELL CULTURE; COMPLEX FORMATION; GENE REPRESSION; GENETIC TRANSCRIPTION; IMMUNOBLOTTING; NEGATIVE FEEDBACK; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; TRANSACTIVATION;

EID: 0033082231     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1097-2765(00)80309-3     Document Type: Article

References (40)

1. Bremner, R., Du, D.C., Connolly-Wilson, M.J., Bridge, P., Ahmad, K.F., Mostachfi, H., Rushlow, D., Dunn, J.M., and Gallie, B. (1997). Deletion of Rb exons 24 and 25 causes low-penetrance retinoblastoma. Am. J. Hum. Genet. 61, 556-570.
2. Chen, J., Lin, J., and Levine, A.J. (1995). Regulation of transcription functions of the p53 tumor suppressor by the mdm2 oncogene. Mol. Med. 1, 142-152.
3. Chew, Y.P., Ellis, M., Wilkie, S., and Mittnacht, S. (1998). pRb phosphorylation mutants reveal role of pRb in regulating S phase completion by a mechanism independent of E2F. Oncogenes 17, 2177-2186.
4. Chow, K.N.B., and Dean, D.C. (1996). Domains A and B in the Rb pocket interact to form a transcriptional repressor motif. Mol. Cell. Biol. 16, 7173-7181.
5. Cordon-Cardo, C., Zhang, Z.F., Dalbagni, G., Dorbnjak, M., Charytonowicz, E., Hu, S.X., Xu, H.J., Reuter, V.E., and Benedict, W.F. (1997). Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res. 57, 1217-1221.
6. Crook, T., Marston, N.J., Sara, E.A., and Vousden, K.H. (1994). Transcription activation by p53 correlates with suppression of growth but not transformation. Cell 79, 817-827.
7. Fredersdorf, S., Burns, J., Milne, A.M., Packham, G., Fallis, L., Gillett, C.E., Royds, J.A., Peston, D., Hall, P.A., Hanby, A.M., et al. (1997). High level expression of p27kip1 and cyclin D1 in some proliferating breast tumor cells: Inverse correlation with the degree of malignancy in human breast and colorectal cancers. Proc. Natl. Acad. Sci. USA 94, 6380-6385.
8. Fuchs, B., O'Connor, D., Fallis, L., Sheidtmann, K.H., and Lu, X. (1995). p53 phosphorylation mutants retain transcription activity. Oncogene 10, 789-793.
9. Harlow, E.E., and Lane, D.P. (1988). Antibodies: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press).
10. Haupt, Y., Barak, Y., and Oren, M. (1996). Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J. 15, 1596-1606.
11. Hofmann, F., Martelli, F., Livingston, D.M., and Wang, Z. (1996). The retinoblastoma gene product protects E2F-1 from degradation by the ubiquitin-proteosome pathway. Genes Dev. 10, 2949-2959.
12. Holmberg, C., Helin, K., Sehested, M., and Karlstrom, O. (1998). E2F-1-induced p53-independent apoptosis in transgenic mice. Oncogene 17, 143-155.
13. Hsieh, J.-K., Fredersdorf, S., Kauzarides, T., Martin, K., and Lu, X. (1997). E2F1 induced apoptosis requires DNA binding but not transcriptional activity and is inhibited by the retinoblastoma protein through direct interaction. Genes Dev. 11, 1840-1852.
14. Hupp, T.R., and Lane, D.P. (1995). Two distinct signaling pathways activate the latent DNA binding function of p53 in a casein kinase II-independent manner. J. Biol. Chem. 270, 18165-18174.
15. Hupp, T.R., Meek, D.W., Midgley, C.A., and Lane, D.P. (1992). Regulation of the specific DNA binding function of p53. Cell 71, 875-886.
16. Jones, S.N., Sands, A.T., Hancock, A.R., Vogel, H., Donehower, L.A., Linke, S.P., Wahl, G.M., and Bradley, A. (1996). The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2. Proc. Natl. Acad. Sci. USA 93, 14106-14111.
17. Knudson, M.K., Tung, K., Tourtellotte, G., Brown, G.A.J., and Korsmmer, S.J. (1995). Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 270, 96-98.
18. Ko, L.J., and Prives, C. (1996). p53: Puzzle and paradigm. Genes Dev. 10, 1054-1072.
19. Kubbutat, M.H., Jones, S.N., and Vousden, K.H. (1997). Regulation of p53 stability by mdm2. Nature 387, 299-303.
20. Levine, A.J. (1997). p53, the cellular gatekeeper for growth and division. Cell 88, 323-331.
21. Lu, X., Burbidge, S.A., Griffin, S., and Smith, H.M. (1996). Discordance between accumulated p53 protein level and its transcriptional activity in response to UV radiation. Oncogene 13, 413-418.
22. Macleod, K.F., Hu, Y., and Jacks, T. (1996). Loss of Rb activates both p53-dependent and independent cell death pathways in the developing mouse nervous system. EMBO J. 15, 6178-6188.
23. Martin, K., Trouche, D., Hagemeier, C., Sorensen, T.S., La Thangue, N.B., and Kouzarides, T. (1995). Stimulation of E2F1/DP1 transcriptional activity by mdm2 oncoprotein. Nature 375, 691-694.
24. Mittnacht, S. (1998). Control of Rb phosphorylation. Curr. Opin. Genet. Dev. 8, 21-27.
25. Morgenbesser, S.D., Williams, B.O., Jacks, T., and Depino, R.A. (1994). p53-dependent apoptosis produced by Rb-deficiency in the eye. Nature 371, 72-74.
26. O'Connor, D.J., Lam, E.W.-F., Griffin, S., Zhong, S., Leighton, L.C., Burbidge, S.A., and Lu, X. (1995). Physical and functional interactions between p53 and cell cycle co-operating transcription factors, E2F1 and DP1. EMBO 14, 6184-6192.
27. Pan, H., Yin, C., Dyson, N.J., Harlow, E., Yamasaki, L., and Van Dyke, T. (1998). Key roles for E2F1 in signaling p53-dependent apoptosis and cell division within developing tumors. Mol. Cell 2, 283-292.
28. Prives, C. (1998). Signaling to p53: Breaking the mdm2-p53 circuit. Cell 95, 5-8.
29. Rowan, S., Ludwig, R.L., Haupt, Y., Bates, S., Lu, X., Oren, M., and Vousden, K.H. (1996). Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO 15, 827-838.
30. Sabbatini, P., Han, J., Chiou, S.-K., Nicholson, D.W., and White, E. (1997). Interleukin 1b converting enzyme-like proteases are essential for p53-mediated transcriptionally dependent apoptosis. Cell Growth Differ. 8, 643-653.
31. Sherr, C.J. (1996). Cancer cell cycle. Science 274, 1672-1677.
32. Thut, C., Goodrich, J.A., and Tjian, R. (1997). Repression of p53-mediated transcription by MDM2: A dual mechanism. Genes Dev. 11, 1974-1986.
33. Tsai, K.Y., Hu, Y., Macleod, K.F., Crowley, D., Yamasaki, L., and Jacks, T. (1998). Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. Mol. Cell 2, 293-304.
34. Weinberg, R.A. (1995). The retinoblastoma protein and cell cycle control. Cell 81, 323-330.
35. Weintraub, S.J., Chow, K.N.B., Luo, R.X., Zhang, S., He, S., and Dean, D.C. (1995). Mechanism of active transcriptional repression by the retinoblastoma protein. Nature 375, 812-815.
36. Welch, P.J., and Wang, J.Y.J. (1993). A c-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle. Cell 75, 779-790.
37. Wu, X., and Levine, A.J. (1994). p53 and E2F-1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci. USA 91, 3602-3606.
38. Xiao, Z.X., Chen, J., Levine, A., Modjtahedl, N., Xing, J., Sellers, W.R., and Livingston, D.M. (1995). Interactions between the retinoblastoma protein and the oncoprotein mdm2. Nature 375, 694-697.
39. Xu, H.J., Quinlan, D.C., Davidson, A.G., Hu, S.X., Summers, C.L., and Benedict, W.F. (1994). Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J. Natl. Cancer Inst. 86, 695-699.
40. Xu, H.-J., Cagle, P.T., Hu, S.-X., Li, J., and Benedict, W.F. (1995). Altered retinoblastoma and p53 protein status in non-small cell carcinoma of the lung: Potential synergistic effects on prognosis. Clin. Cancer Res. 2, 1169-1176.